论文部分内容阅读
目的:探讨纤溶酶原激活物抑制物-1(PAI-1)、转化生长因子-β1(TGF-β1)在宫颈癌中的表达及其在宫颈癌发生、发展中的作用。方法:采用Envision二步免疫组织化学方法检测宫颈癌石蜡包埋组织(63例,分为原位癌组、高分化组、中低分化组)与正常宫颈石蜡包埋组织(15例,对照组)中PAI-1、TGF-β1的表达。结果:(1)PAI-1在对照组、宫颈原位癌组、高分化组、中低分化组中的阳性表达率分别为0(0/15)、75.00%(6/8)、51.85%(14/27)、82.14%(23/28);对照组0(0/15)与宫颈癌组68.25%(43/63)间PAI-1蛋白阳性表达率差异有统计学意义(P<0.01);宫颈癌各组间PAI-1蛋白阳性表达率差异有统计学意义(P<0.01),PAI-1与病理分级有相关性。(2)TGF-β1在对照组、宫颈原位癌组、高分化组、中低分化组的细胞胞浆中的阳性表达率分别为13.33%(2/15)、25.00%(2/8)、48.15%(13/27)、71.43%(20/28);对照组13.33%(2/15)与宫颈癌组55.56%(35/63)间TGF-β1蛋白阳性表达率差异有统计学意义(P<0.01);TGF-β1在各组间细胞胞浆中阳性表达率差异有统计学意义(P<0.01),与病理分级有关;而在各组细胞外基质中的阳性表达率分别为13.33%(2/15)、37.50%(3/8)、22.22%(6/27)、42.86%(12/28);对照组与宫颈癌组33.33%(21/63)间基质中TGF-β1表达率差异无统计学意义(P>0.05)。(3)在宫颈癌中TGF-β1对PAI-1的表达有正协同作用(r=0.282,P<0.05);其表达率与年龄、民族无关。结论:在宫颈癌组织中PAI-1、TGF-β1的异常表达提示与肿瘤的发生、发展密切相关,并促进肿瘤的浸润与转移,联合检测PAI-1、TGF-β1有可能成为预测子宫颈癌发展及预后的重要指标。
Objective: To investigate the expression of plasminogen activator inhibitor-1 (PAI-1) and transforming growth factor-β1 (TGF-β1) in cervical cancer and its role in the development and progression of cervical cancer. Methods: Envision immunohistochemistry was used to detect the expression of paraffin embedded tissue of cervical cancer (63 cases, in situ carcinoma group, well differentiated group, moderately poorly differentiated group) and normal cervical paraffin embedded tissue (15 cases, control group ) PAI-1, TGF-β1 expression. Results: (1) The positive rates of PAI-1 in control group, cervical carcinoma in situ, high differentiated group and moderately poorly differentiated group were 0 (0/15), 75.00% (6/8), 51.85% (14/27) and 82.14% (23/28), respectively. The positive rate of PAI-1 protein in the control group 0 (0/15) and cervical cancer group 68.25% (43/63) was significantly different ). The positive rate of PAI-1 protein in cervical cancer was significantly different between groups (P <0.01). There was a correlation between PAI-1 and pathological grade. (2) The positive rates of TGF-β1 in the cytoplasm of control group, cervical carcinoma in situ, well-differentiated group and poorly-differentiated group were 13.33% (2/15) and 25.00% (2/8), respectively , 48.15% (13/27) and 71.43% (20/28) respectively. The positive expression rate of TGF-β1 in 13.33% (2/15) and 55.56% (35/63) cases of cervical cancer was significantly different (P <0.01). The positive expression rate of TGF-β1 in the cytoplasm of each group was significantly different (P <0.01), which was related to the pathological grade. The positive expression rates of TGF-β1 in the extracellular matrix of each group were 13.33% (2/15), 37.50% (3/8), 22.22% (6/27) and 42.86% (12/28), respectively. In the control group and cervical cancer group, 33.33% (21/63) β1 expression rate difference was not statistically significant (P> 0.05). (3) There was a positive synergistic effect of TGF-β1 on the expression of PAI-1 in cervical cancer (r = 0.282, P <0.05). The expression rate of TGF-β1 was not related to age and ethnicity. Conclusion: The abnormal expressions of PAI-1 and TGF-β1 in cervical cancer suggest that they are closely related to the occurrence and development of tumor and promote the infiltration and metastasis of tumor. Combined detection of PAI-1 and TGF-β1 may be predictors of cervical Cancer development and prognosis of the important indicators.